personalizing treatment of transfusion-dependent anemia in lr-mds
Published 2 weeks ago • 16 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
3:21
an insight into the standard of care in hr-mds and future outlooks
-
2:43
novel therapies in the future of mds treatment
-
1:43
reasons why there are fewer treatment options for mds patients and hope for the future
-
1:14
how the ipss-m score helps personalizing treatment & combination therapies in hr-mds
-
1:30
the prognostic value of patient-reported outcomes in mds
-
3:38
a new set of treatment options for low-risk mds
-
1:02
maintenance therapy following treatment for amyloidosis
-
1:04
the future of mds management
-
1:35
ipss-m: prognostic power in hma-treated mds patients
-
2:16
current and future treatment approaches for hr-mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
1:17
exciting novel treatments being developed for mds
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
4:44
keynote-183 and optimismm: creating new standards of care for r/r mm
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds